Tvardi Therapeutics, Inc. Common Stock
TVRDTvardi Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for inflammatory and fibrotic diseases. The company leverages its proprietary drug discovery platform to identify and advance small-molecule treatments aimed at challenging conditions, with an emphasis on improving patient outcomes.
Company News
The idiopathic pulmonary fibrosis (IPF) treatment landscape is expanding with 80+ companies developing 100+ novel therapies across various clinical stages. Growing disease awareness and diagnostic improvements are driving demand for more effective treatments beyond current antifibrotic limitations. Key developments include orphan drug designation...
Tvardi Therapeutics (NASDAQ: TVRD) experienced an 80% stock decline on October 13, 2025, after disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and lung function outcomes. A securities law firm is now investigating potent...
Tvardi Therapeutics' stock plummeted over 80% on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its primary goals regarding safety and efficacy outcomes. Securities law firm Faruqi & Faruqi is investigating potential claims on...
Tvardi Therapeutics experienced significant stock decline after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
Tvardi Therapeutics experienced an 80% stock drop after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
